QTRX

Over the past six months (April 2026 - October 2026), Quanterix Corp. reported its second-quarter 2026 financial results on August 10, 2026, with revenue of $32.9 million (a 34% increase year-over-year) and an improved adjusted EBITDA loss of $10.0 million. However, the company's earnings missed estimates by $0.64 and revenue fell short of expectations, leading to a significant stock price decline, including a -40% largest daily move on August 10, 2026. This performance prompted Canaccord to cut Quanterix's stock price target, and the stock reached an all-time low of $2.15 USD on August 9, 2026. Other notable events include the appointment of Jim Gute as Chief Commercial Officer on August 10, 2026, and Dr. Yuri Fesko as Chief Medical Officer on September 15, 2026. The company also reported inducement grants under Nasdaq Listing Rule 5635(c)(4) on June 16, 2026, and July 16, 2026. In September 2026, Quanterix announced progress on its spatial biology content innovation, including the global release of its PhenoCode 2.0 Molecular Barcoding Kit. As of October 1, 2026, the share price was $3.41, representing a decline of 39.65% from October 2, 2025.